Comment on: F.M. Scherer, "How US Antitrust Can Go Astray: The Brand Name Prescription Drug Litigation"

Peter Zweifel

International Journal of the Economics of Business, 1997, vol. 4, issue 3, 277-278

Keywords: Antitrust policy; Price discrimination; Patent protection; Pharmaceutical industry, JEL classifications: K21, L41, Kll, L65, (search for similar items in EconPapers)
Date: 1997
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://www.tandfonline.com/10.1080/758523209 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:taf:ijecbs:v:4:y:1997:i:3:p:277-278

Ordering information: This journal article can be ordered from
http://www.tandfonline.com/pricing/journal/CIJB20

DOI: 10.1080/758523209

Access Statistics for this article

International Journal of the Economics of Business is currently edited by Eleanor Morgan

More articles in International Journal of the Economics of Business from Taylor & Francis Journals
Bibliographic data for series maintained by Chris Longhurst ().